Cogent Biosciences Inc’s recent filing unveils that its Director Fairmount Funds Management LLC acquired Company’s shares for reported $25.0 million on Jul 10 ’25. In the deal valued at $9.00 per share,2,777,777 shares were bought. As a result of this transaction, Fairmount Funds Management LLC now holds 9,003,418 shares worth roughly $98.68 million.
Then, Pinnow Cole bought 43,750 shares, generating $332,412 in total proceeds. Upon buying the shares at $7.60, the Chief Commercial Officer now owns 45,848 shares.
Scotiabank initiated its Cogent Biosciences Inc [COGT] rating to a Sector outperform in a research note published on March 07, 2025; the price target was $17. A number of analysts have revised their coverage, including Needham’s analysts, who decreased its forecast for the stock in mid December from “a Buy” to “a Hold”. Robert W. Baird also remained covering COGT and has decreased its forecast on February 26, 2024 with a “Neutral” recommendation from previously “an Outperform” rating. Citigroup started covering the stock on February 08, 2024. It rated COGT as “a Buy”.
Price Performance Review of COGT
On Friday, Cogent Biosciences Inc [NASDAQ:COGT] saw its stock jump 0.92% to $10.96. Over the last five days, the stock has lost -3.86%. Cogent Biosciences Inc shares have risen nearly 18.36% since the year began. Nevertheless, the stocks have risen 40.51% over the past one year.
How much short interest is there in Cogent Biosciences Inc?
A steep rise in short interest was recorded in Cogent Biosciences Inc stocks on 2025-07-15, dropping by -2.76 million shares to a total of 13.76 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 16.52 million shares. There was a decline of -20.08%, which implies that there is a negative sentiment for the stock.
